- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,498GBP
- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,498GBP
- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,498GBP
- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,498GBP
- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,498GBP
- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,498GBP
- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,498GBP
- Report
- February 2026
- 250 Pages
Global
From €4083EUR$4,490USD£3,498GBP
- Report
- July 2026
- 488 Pages
Global
From €5320EUR$5,850USD£4,558GBP
- Report
- July 2026
- 364 Pages
Global
From €5320EUR$5,850USD£4,558GBP
- Report
- July 2026
- 382 Pages
Global
From €5320EUR$5,850USD£4,558GBP
- Report
- July 2026
- 282 Pages
Global
From €5320EUR$5,850USD£4,558GBP
- Report
- April 2026
- 195 Pages
Global
From €4320EUR$4,750USD£3,701GBP
- Report
- April 2026
- 136 Pages
Global
From €3637EUR$3,999USD£3,116GBP
- Report
- October 2025
- 198 Pages
Global
From €4092EUR$4,500USD£3,506GBP
- Report
- July 2025
- 350 Pages
Global
From €4501EUR$4,949USD£3,856GBP
- Report
- May 2026
- 150 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 145 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 149 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 151 Pages
Global
From €3592EUR$3,950USD£3,078GBP

Prostate cancer is a type of cancer that affects the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is the most common cancer in men in the United States, and the second most common cause of cancer death in men. Prostate cancer is typically treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these treatments.
The prostate cancer market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to benefit from the introduction of novel therapies, such as immunotherapies and targeted therapies, which are expected to improve the prognosis of patients. Additionally, the increasing focus on early diagnosis and the development of new diagnostic tools are expected to drive the market growth.
Some of the key players in the prostate cancer market include AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more